EMA/351976/2023

European Medicines Agency decision

P/0336/2023

of 7 August 2023

on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (EMEA-000727-PIP01-09-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0336/2023

of 7 August 2023

on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (Bosulif), (EMEA-000727-PIP01-09-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/170/2010 issued on 3 September 2010, the decision P/0016/2016 issued on 29 January 2016, the decision P/0325/2016 issued on 2 December 2016, the decision P/0282/2019 issued on 14 August 2019, the decision P/0270/2020 issued on 17 July 2020, the decision P/0368/2021 issued on 8 September 2021 and the decision P/0279/2022 issued on 10 August 2022,

Having regard to the application submitted by Pfizer Europe MA EEIG on 21 April 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for bosutinib (Bosulif), hard capsule, film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 - Brussels Belgium.

EMA/PDCO/213802/2023 Corr[1]
Amsterdam, 21 July 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000727-PIP01-09-M07

Scope of the application

Active substance(s):

Bosutinib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of chronic myeloid leukaemia

Pharmaceutical form(s):

Hard capsule

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Europe MA EEIG

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted to the European Medicines Agency on 21 April 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/170/2010 issued on 3 September 2010, the decision P/0016/2016 issued on 29 January 2016, the decision P/0325/2016 issued on 2 December 2016, the decision P/0282/2019 issued on 14 August 2019, the decision P/0270/2020 issued on 17 July 2020, the decision P/0368/2021 issued on 8 September 2021 and the decision P/0279/2022 issued on 10 August 2022.

[1] 1 August 2023

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 22 May 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic myeloid leukaemia (CML)

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- hard capsule, film-coated tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of chronic myeloid leukaemia (CML)

2.1.1. Indication(s) targeted by the PIP

- Treatment of newly diagnosed chronic phase CML in children and adolescents (from 1 to less than 18 years of age)
- Treatment of chronic, accelerated or blast phase CML in children and adolescents with resistance or intolerance to prior therapy including imatinib

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

- age-appropriate hard capsule of 25 mg and 50 mg
- film-coated tablet of 100 mg and 500 mg

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of age-appropriate hard capsules
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Study 2 was removed in procedure EMEA-000727-PIP01-09-M01

	Study 3 Bioequivalence study in adults with bosutinib age-appropriate hard capsules **Study 4** Two-phase study, a 6+4 dose escalation phase to determine a recommended phase 2 dose based on tolerability and PK of bosutinib and an open-label, non-controlled phase to evaluate anti-leukemic activity (determined by central laboratory analysis of cytogenetic and molecular response data), safety, tolerability, and PK of bosutinib
Modelling and simulation studies	Not applicable
Other studies	Not applicable
Extrapolation plan	Study 4 is part of an extrapolation plan covering the paediatric population from 1 year to less than 18 years of age, as agreed by the PDCO *Added in procedure EMEA-000727-PIP01-09-M07.*

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2022
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of chronic myeloid leukaemia

Authorised indication(s):

Bosulif is indicated for the treatment of adult patients with:

- newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML);
- CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
  - Invented name(s): Bosulif
  - Authorised pharmaceutical form(s): film-coated tablet
  - Authorised route(s) of administration: oral use
  - Authorised via centralised procedure.